These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics. Shah A; Xie L; Kariburyo F; Zhang Q; Gore M Adv Ther; 2018 Nov; 35(11):1994-2014. PubMed ID: 30269292 [TBL] [Abstract][Full Text] [Related]
24. The Role of Attitudes Toward Medication and Treatment Adherence in the Clinical Response to LAIs: Findings From the STAR Network Depot Study. Aguglia A; Fusar-Poli L; Amerio A; Placenti V; Concerto C; Martinotti G; Carrà G; Bartoli F; D'Agostino A; Serafini G; Amore M; Aguglia E; Ostuzzi G; Barbui C; Front Psychiatry; 2021; 12():784366. PubMed ID: 34975581 [No Abstract] [Full Text] [Related]
25. Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study. García Álvarez JC; González Sánchez L; García Resa E; Bonete Llácer JM; Román Rodríguez A; Pecino Esquerdo B; Pérez Martínez E Int J Psychiatry Clin Pract; 2020 Mar; 24(1):10-17. PubMed ID: 31933402 [No Abstract] [Full Text] [Related]
26. Satisfaction Survey on Antipsychotic Formulations by Schizophrenia Patients in Japan. Hatano M; Takeuchi I; Yamashita K; Morita A; Tozawa K; Sakakibara T; Hajitsu G; Hanya M; Yamada S; Iwata N; Kamei H Clin Psychopharmacol Neurosci; 2021 Nov; 19(4):610-617. PubMed ID: 34690116 [TBL] [Abstract][Full Text] [Related]
27. Baseline results from the European non-interventional Antipsychotic Long acTing injection in schizOphrenia (ALTO) study. Llorca PM; Bobes J; Fleischhacker WW; Heres S; Moore N; Bent-Ennakhil N; Sapin C; Loze JY; Nylander AG; Patel MX Eur Psychiatry; 2018 Aug; 52():85-94. PubMed ID: 29734130 [TBL] [Abstract][Full Text] [Related]
28. [French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics]. Samalin L; Abbar M; Courtet P; Guillaume S; Lancrenon S; Llorca PM Encephale; 2013 Dec; 39 Suppl 4():189-203. PubMed ID: 24373464 [TBL] [Abstract][Full Text] [Related]
29. Three-Year Naturalistic Study On Early Use Of Long-Acting Injectable Antipsychotics In First Episode Psychosis. Medrano S; Abdel-Baki A; Stip E; Potvin S Psychopharmacol Bull; 2018 Jun; 48(4):25-61. PubMed ID: 30618474 [TBL] [Abstract][Full Text] [Related]
30. Treatment patterns and health care resource utilization in a 1-year observational cohort study of outpatients with schizophrenia at risk of nonadherence treated with long-acting injectable antipsychotics. Bernardo M; San L; Olivares JM; Dilla T; Polavieja P; Gilaberte I; Alvarez M; Ciudad A Patient Prefer Adherence; 2011; 5():601-10. PubMed ID: 22259237 [TBL] [Abstract][Full Text] [Related]
31. Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: a randomized effectiveness study. Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa-McMillan A J Clin Psychiatry; 2012 Sep; 73(9):1224-33. PubMed ID: 22938760 [TBL] [Abstract][Full Text] [Related]
32. Drug Attitude, Insight, and Patient's Knowledge About Prescribed Antipsychotics in Schizophrenia: A Cross-Sectional Survey. Nagai N; Tani H; Yoshida K; Gerretsen P; Suzuki T; Ikai-Tani S; Mimura M; Uchida H Neuropsychiatr Dis Treat; 2020; 16():781-787. PubMed ID: 32256074 [TBL] [Abstract][Full Text] [Related]
33. Indications for and use of long-acting injectable antipsychotics: consideration from an inpatient setting. Kishimoto T; Sanghani S; Russ MJ; Marsh AN; Morris J; Basu S; John M; Kane JM Int Clin Psychopharmacol; 2017 May; 32(3):161-168. PubMed ID: 28181959 [TBL] [Abstract][Full Text] [Related]
34. Patients' Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire. Blackwood C; Sanga P; Nuamah I; Keenan A; Singh A; Mathews M; Gopal S Patient Prefer Adherence; 2020; 14():1093-1102. PubMed ID: 32753849 [TBL] [Abstract][Full Text] [Related]
35. Use of Long-Acting Injectable Antipsychotics in Inpatients with Schizophrenia Spectrum Disorder in an Academic Psychiatric Hospital in Switzerland. Reymann S; Schoretsanitis G; Egger ST; Mohonko A; Kirschner M; Vetter S; Homan P; Seifritz E; Burrer A J Pers Med; 2022 Mar; 12(3):. PubMed ID: 35330441 [TBL] [Abstract][Full Text] [Related]
36. Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting, intramuscular, antipsychotic medications. Aggarwal NK; Sernyak MJ; Rosenheck RA J Clin Psychopharmacol; 2012 Jun; 32(3):323-8. PubMed ID: 22544006 [TBL] [Abstract][Full Text] [Related]
37. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists]. Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914 [TBL] [Abstract][Full Text] [Related]
38. Converting oral to long-acting injectable antipsychotics: a guide for the perplexed. Meyer JM CNS Spectr; 2017 Dec; 22(S1):14-28. PubMed ID: 29350127 [TBL] [Abstract][Full Text] [Related]
39. Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic. Pilon D; Joshi K; Tandon N; Lafeuille MH; Kamstra RL; Emond B; Lefebvre P Patient Prefer Adherence; 2017; 11():619-629. PubMed ID: 28356723 [TBL] [Abstract][Full Text] [Related]